Data from the current study showed that the prevalence of pulmonary involvements, especially ILD, was increased in patients with anti-Ro52 antibodies alone compared with the other two groups (anti-Ro60 alone and combined anti-Ro52 and anti-Ro60 antibodies). Here, RO60 is linked to interstitial lung disease.